Report type: Weekly Strategy
“Investments and Important News Supported by Demand Due to National Policy”
After the Nikkei average fell to 25,621 points on the 3rd of this month, it rebounded to 27,399 points on the 6th 3 business days later. It then reversed 4 business days later on the 13th and fell to 26,237 points. Then, on the 14th, the next business day after the announcement of the U.S. Consumer Price Index (CPI) for September, it rose sharply by over 900 points compared to the previous day’s closing price. As evidenced from this, the Japanese stock market has had a turn of events with high volatility (variability). The “Nikkei Stock Average VI (Volatility Index)”, which is an estimated value of the amount of fluctuation in the next month of the Nikkei average, has also increased to exceed 25% recently after falling under 20 points a month ago.
In the midst of this, mainly on the news we come across on the daily TV, etc., there have been successive appearances of “the old-school” backed by national policy as investment topics and targets for individual stocks.
① As though to coincide with the significant easing of border control measures related to COVID-19 from the 11th, Japan Airlines (9201) renewed its record high since March 2020 after the emergence of COVID-19. The comprehensive logistics Konoike Transport (9025), which was featured in “Selected Stocks” in last week’s issue, also increased their handled volume for the time being, such as in the resumption of flights for domestic and international travelers in those related to airports and are similarly renewing their record high since March ’20.
② Japanese Prime Minister Kishida proposed 3 pillars regarding “investment in people” that will invest 1 trillion yen over 5 years, which are “the new establishment and expansion of support for enterprises accepting occupational changes and side jobs, etc.”, “Creating initiatives to support occupational changes for the purpose of career advancement of enterprise workers” and “increasing support for enterprises working on re-educating employees”.
③ The Japanese government announced countermeasures to prepare for the simultaneous outbreak of COVID-19 and seasonal flu this winter. Since those who have a fever and are at low risk of it worsening are urged to self-test first and outpatients with fevers are to recover at home as much as possible by taking antipyretics and analgesics without going for a medical examination, they have called for its citizens to purchase medicines and COVID-19 rapid antigen test kits in advance. They are also considering initiatives such as to enable anti-influenza drugs to be prescribed online and delivered to homes, etc.
④ On the 13th, the Japanese government officially announced the policy to scrap the present health insurance card in autumn 2024 and switch to the “individual number health insurance card”, which is integrated with the Individual Number Card. We can anticipate it to benefit system vendors that have strengths in administrative organizations. Digital Minister Kono is said to also be considering bringing forward the implementation of the “individual Number Driver’s License” which enables it to have the function of one’s driver’s license in their Individual Number Card.
⑤ There have been successive ballistic missile firings by North Korea and them landing outside of Japan’s Exclusive Economic Zone (EEZ). It is said that the missile firings also include military involvement by the “tactical nuclear weapons operational troops”, and on the 4th, it was announced that the missile that passed through the sky in offshore Aomori Prefecture was also “a new model of the surface-to-surface intermediate and long-range ballistic missile”. There is a possibility of an increase in demand for products and services never seen before in Japan, such as housing equipped with underground nuclear bomb shelters.
In the 17/10 issue, we will be covering Mitsui Matsushima Holdings (1518), Denka (4061), Fukui Computer Holdings (9790) and Autobacs Seven (9832).
Mitsui Matsushima Holdings Co., Ltd. (1518) 3,035 yen (14/10 closing price)
・Established by acquiring a coal mining area in Matsushima district, Nagasaki Prefecture in 1913. Manages the lifestyle-related business (materials for consumption, clothing, electronic components, business equipment, etc.) in addition to the energy business (coal production/retail and renewable energy), etc.
・For 1Q (Apr-Jun) results of FY2023/3 announced on 5/8, net sales increased by 33.7% to 14.197 billion yen compared to the same period the previous year and operating income increased by 3.3 times to 3.495 billion yen. For the lifestyle-related business, net sales increased by 28% to 8.16 billion yen and operating income increased by 48% to 1.061 billion yen. For the energy business, net sales increased by 44% to 5.708 billion yen and operating income increased by 5.0 times to 2.788 billion yen.
・Company revised its full year plan upwards. In response to the rise in coal prices in coal production, net sales is expected to increase by 50.2% to 70 billion yen compared to the previous year (original plan 57 billion yen), operating income to increase by 2.8 times to 23.2 billion yen (original plan 14.3 billion yen) and annual dividend to have a 150 yen dividend increase to 230 yen (original plan 160 yen). With restrictions due to an export embargo in the Russian-made supply, which has the second largest share after Australia, the international price of coal for power generation fuel (general coal) has a stronger downward rigidity of price compared to crude oil and natural gas.
Denka Company Limited (4061) 3,225 yen (14/10 closing price)
・A synthetic chemicals company that established in 1915. Famous for their trademark of a military leader’s fan seal involving chemical fertilizers and cement. Their main businesses are electronics / cutting-edge products, life innovation, elastomers and infrastructure solutions, and polymer solutions.
・For 1Q (Apr-Jun) results of FY2023/3 announced on 5/8, net sales increased by 8.8% to 94.369 billion yen compared to the same period the previous year and operating income decreased by 36.7% to 4.902 billion yen. Although there was an increase in revenue from the increase in net income due to the depreciation of the yen and revised retail prices to match the sharp rise in the price of raw materials and fuel, in the profit aspect, increased costs following an advancement in specialization and a worsening of the terms of trade have affected.
・For its full year plan, net sales is expected to increase by 18.2% to 455 billion yen compared to the previous year, operating income to increase by 7.2% to 43 billion yen and annual dividend to remain unchanged at 145 yen. To prepare for the strain in medical sites due to a surge in patients if there is a simultaneous outbreak of seasonal flu and COVID-19 this winter, the Ministry of Health, Labour and Welfare has called for increased production by domestic and overseas manufacturers including the company which have obtained approval by the Ministry of Health, Labour and Welfare to manufacture and retail antigen test kits that are able to identify both at the same time.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
